Abstract :
[en] A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical onset of Parkinson's disease (PD). Studies have identified several different prodromal markers that may have the potential to predict the conversion from healthy to clinical PD but use considerably different approaches. We systematically reviewed 35 longitudinal studies reporting prodromal PD features and evaluated the methodological quality across 10 different predefined domains. We found limitations in the following domains: PD diagnosis (57% of studies), prodromal marker assessments (51%), temporal information on prodromal markers or PD diagnosis (34%), generalizability of results (17%), statistical methods (accounting for at least age as confounder; 17%), study design (14%), and sample size (9%). However, no limitations regarding drop-out (or bias investigation), or report of inclusion/exclusion criteria or
prodromal marker associations were revealed. Lessons learned from these limitations
and additional aspects of current prodromal marker studies in PD are discussed to
provide a basis for the evaluation of findings and the improvement of future research in
prodromal PD. The observed heterogeneity of studies, limitations and analyses might be
addressed in future longitudinal studies using a, yet to be established, modular minimal
set of assessments improving comparability of findings and enabling data sharing and
combined analyses across studies.
Scopus citations®
without self-citations
20